Literature DB >> 8342051

The effects of intraarticular administration of hyaluronan in a model of early osteoarthritis in sheep. II. Cartilage composition and proteoglycan metabolism.

P Ghosh1, R Read, Y Numata, S Smith, S Armstrong, D Wilson.   

Abstract

A model of early osteoarthritis (OA) induced in ovine joints by medial meniscectomy was used to study the effects of two hyaluronan (HA) preparations (AHA and DHA) on cartilage composition and proteoglycan (PG) metabolism. DHA was an HA preparation with an average molecular weight (MW) of approximately 2.0 x 10(6) d, and AHA had an MW of approximately 8.0 x 10(5) d. Both preparations were administered intraarticularly once a week for 5 weeks starting 16 weeks after meniscectomy, and animals (n = 5) were killed 5 weeks after the last injection. Meniscectomized, saline-injected (n = 5) and nonoperated (n = 5) animals were used for controls. At necropsy, 3-mm-diameter full-depth cartilage plugs were sampled under sterile conditions from specific locations on the medial and lateral femoral condyles, tibial plateaus, patella, and trochlear groove. The cartilage plugs were cultured in Hams-F12 medium supplemented with 10% fetal calf serum for 24 hours, then for a further 48 hours in the presence of H2(35)SO4 to determine the biosynthesis of PGs. The percentage of 35S-PGs and sulfated glycosaminoglycans released into the media was also ascertained. The cartilage adjacent to the plugs was analyzed for collagen and proteoglycan content and differential extractability with guanidine hydrochloride (GuHCl) solutions. The extractability of PGs with 0.4 mol/L GuHCl (nondissociative conditions) was lower from the medial femoral cartilages of the DHA-treated group than from the corresponding saline-treated group. In contrast, the release of 35S-PGs from the tibial cartilages of the DHA-treated animals was higher than in the saline-treated group. The biosynthesis of 35S-PGs, determined in vitro, for cartilage derived from the medial compartment was generally lower than for the lateral regions of the meniscectomized joints. The biosynthetic activity was further reduced in joints injected with the two HA preparations, but DHA reduced 35SO4 incorporation into PGs more than AHA. It was concluded that reduced biosynthesis of 35S-PGs and secretion into media was a consequence of increased loading of joints in the HA-treated animals rather than a direct effect of these preparations on chondrocyte metabolism.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8342051     DOI: 10.1016/s0049-0172(10)80017-4

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  12 in total

1.  Comparative spatial and temporal localisation of perlecan, aggrecan and type I, II and IV collagen in the ovine meniscus: an ageing study.

Authors:  James Melrose; Susan Smith; Martin Cake; Richard Read; John Whitelock
Journal:  Histochem Cell Biol       Date:  2005-10-28       Impact factor: 4.304

Review 2.  Nonsteroidal anti-inflammatory drugs and chondroprotection. A review of the evidence.

Authors:  P Ghosh
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

3.  Intra-articular hyaluronan treatment for osteoarthritis.

Authors:  E George
Journal:  Ann Rheum Dis       Date:  1998-11       Impact factor: 19.103

4.  Effects of low and high molecular weight hyaluronic acid on the osteoarthritic temporomandibular joint in rabbit.

Authors:  Veronica Iturriaga; Bélgica Vásquez; Thomas Bornhardt; Mariano Del Sol
Journal:  Clin Oral Investig       Date:  2021-01-03       Impact factor: 3.573

5.  Effects of supplemental intra-articular lubricin and hyaluronic acid on the progression of posttraumatic arthritis in the anterior cruciate ligament-deficient rat knee.

Authors:  Erin Teeple; Khaled A Elsaid; Gregory D Jay; Ling Zhang; Gary J Badger; Matthew Akelman; Thomas F Bliss; Braden C Fleming
Journal:  Am J Sports Med       Date:  2010-09-20       Impact factor: 6.202

6.  Site-specific analysis of gene expression in early osteoarthritis using the Pond-Nuki model in dogs.

Authors:  Aaron M Stoker; James L Cook; Keiichi Kuroki; Derek B Fox
Journal:  J Orthop Surg Res       Date:  2006-10-10       Impact factor: 2.359

7.  Safety and performance of Hydros and Hydros-TA for knee osteoarthritis: a prospective, multicenter, randomized, double-blind feasibility trial.

Authors:  Robert J Petrella; Pieter J Emans; Julia Alleyne; Frank Dellaert; Dawn P Gill; Marcee Maroney
Journal:  BMC Musculoskelet Disord       Date:  2015-03-18       Impact factor: 2.362

8.  Hylan GF-20 Viscosupplementation in the Treatment of Symptomatic Osteoarthritis of the Knee: Clinical Effect Survivorship at 5 Years.

Authors:  Tarek Boutefnouchet; Guru Puranik; Esther Holmes; Karl M Bell
Journal:  Knee Surg Relat Res       Date:  2017-06-01

9.  Evaluation of the symptomatic and structural efficacy of a new hyaluronic acid compound, NRD101, in comparison with diacerein and placebo in a 1 year randomised controlled study in symptomatic knee osteoarthritis.

Authors:  T Pham; A Le Henanff; Ph Ravaud; P Dieppe; L Paolozzi; M Dougados
Journal:  Ann Rheum Dis       Date:  2004-08-26       Impact factor: 19.103

Review 10.  The mechanism of action for hyaluronic acid treatment in the osteoarthritic knee: a systematic review.

Authors:  R D Altman; A Manjoo; A Fierlinger; F Niazi; M Nicholls
Journal:  BMC Musculoskelet Disord       Date:  2015-10-26       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.